275 related articles for article (PubMed ID: 16535861)
1. Neuraminidase inhibitors as antiviral agents.
Alymova IV; Taylor G; Portner A
Curr Drug Targets Infect Disord; 2005 Dec; 5(4):401-9. PubMed ID: 16535861
[TBL] [Abstract][Full Text] [Related]
2. Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro.
Zürcher T; Yates PJ; Daly J; Sahasrabudhe A; Walters M; Dash L; Tisdale M; McKimm-Breschkin JL
J Antimicrob Chemother; 2006 Oct; 58(4):723-32. PubMed ID: 16891631
[TBL] [Abstract][Full Text] [Related]
3. Structural studies of the resistance of influenza virus neuramindase to inhibitors.
Smith BJ; McKimm-Breshkin JL; McDonald M; Fernley RT; Varghese JN; Colman PM
J Med Chem; 2002 May; 45(11):2207-12. PubMed ID: 12014958
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of 6-acetamido-5-amino- and -5-guanidino-3, 4-dehydro-N-(2-ethylbutyryl)- 3-piperidinecarboxylic acids related to zanamivir and oseltamivir, inhibitors of influenza virus neuraminidases.
Shitara E; Nishimura Y; Nerome K; Hiramoto Y; Takeuchi T
Org Lett; 2000 Nov; 2(24):3837-40. PubMed ID: 11101432
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants.
Gubareva LV; Webster RG; Hayden FG
Antimicrob Agents Chemother; 2001 Dec; 45(12):3403-8. PubMed ID: 11709315
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir.
Bantia S; Parker CD; Ananth SL; Horn LL; Andries K; Chand P; Kotian PL; Dehghani A; El-Kattan Y; Lin T; Hutchison TL; Montgomery JA; Kellog DL; Babu YS
Antimicrob Agents Chemother; 2001 Apr; 45(4):1162-7. PubMed ID: 11257030
[TBL] [Abstract][Full Text] [Related]
7. Phenotypic drug susceptibility assay for influenza virus neuraminidase inhibitors.
McSharry JJ; McDonough AC; Olson BA; Drusano GL
Clin Diagn Lab Immunol; 2004 Jan; 11(1):21-8. PubMed ID: 14715540
[TBL] [Abstract][Full Text] [Related]
8. Neuraminidase inhibitors as potential anti-influenza drugs.
Bamford MJ
J Enzyme Inhib; 1996; 10(1):1-16. PubMed ID: 8835926
[No Abstract] [Full Text] [Related]
9. Effect of hemagglutinin glycosylation on influenza virus susceptibility to neuraminidase inhibitors.
Mishin VP; Novikov D; Hayden FG; Gubareva LV
J Virol; 2005 Oct; 79(19):12416-24. PubMed ID: 16160169
[TBL] [Abstract][Full Text] [Related]
10. Utilization of the embryonated egg for in vivo evaluation of the anti-influenza virus activity of neuraminidase inhibitors.
Sauerbrei A; Haertl A; Brandstaedt A; Schmidtke M; Wutzler P
Med Microbiol Immunol; 2006 Jun; 195(2):65-71. PubMed ID: 16059699
[TBL] [Abstract][Full Text] [Related]
11. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility.
Yen HL; Herlocher LM; Hoffmann E; Matrosovich MN; Monto AS; Webster RG; Govorkova EA
Antimicrob Agents Chemother; 2005 Oct; 49(10):4075-84. PubMed ID: 16189083
[TBL] [Abstract][Full Text] [Related]
12. Influenza virus neuraminidase inhibitors.
Gubareva LV; Kaiser L; Hayden FG
Lancet; 2000 Mar; 355(9206):827-35. PubMed ID: 10711940
[TBL] [Abstract][Full Text] [Related]
13. Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir.
Hurt AC; Barr IG; Hartel G; Hampson AW
Antiviral Res; 2004 Apr; 62(1):37-45. PubMed ID: 15026200
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in neuraminidase inhibitor development as anti-influenza drugs.
Feng E; Ye D; Li J; Zhang D; Wang J; Zhao F; Hilgenfeld R; Zheng M; Jiang H; Liu H
ChemMedChem; 2012 Sep; 7(9):1527-36. PubMed ID: 22807317
[TBL] [Abstract][Full Text] [Related]
15. In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675.
Molla A; Kati W; Carrick R; Steffy K; Shi Y; Montgomery D; Gusick N; Stoll VS; Stewart KD; Ng TI; Maring C; Kempf DJ; Kohlbrenner W
J Virol; 2002 Jun; 76(11):5380-6. PubMed ID: 11991966
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of novel hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 against human parainfluenza viruses in vitro and in vivo.
Alymova IV; Taylor G; Takimoto T; Lin TH; Chand P; Babu YS; Li C; Xiong X; Portner A
Antimicrob Agents Chemother; 2004 May; 48(5):1495-502. PubMed ID: 15105096
[TBL] [Abstract][Full Text] [Related]
17. Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors.
McKimm-Breschkin JL; Sahasrabudhe A; Blick TJ; McDonald M; Colman PM; Hart GJ; Bethell RC; Varghese JN
J Virol; 1998 Mar; 72(3):2456-62. PubMed ID: 9499107
[TBL] [Abstract][Full Text] [Related]
18. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir.
McKimm-Breschkin J; Trivedi T; Hampson A; Hay A; Klimov A; Tashiro M; Hayden F; Zambon M
Antimicrob Agents Chemother; 2003 Jul; 47(7):2264-72. PubMed ID: 12821478
[TBL] [Abstract][Full Text] [Related]
19. A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A/H1N1 virus.
Abed Y; Goyette N; Boivin G
Antivir Ther; 2004 Aug; 9(4):577-81. PubMed ID: 15456089
[TBL] [Abstract][Full Text] [Related]
20. Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 2. Crystallographic and molecular modeling study of complexes of 4-amino-4H-pyran-6-carboxamides and sialidase from influenza virus types A and B.
Taylor NR; Cleasby A; Singh O; Skarzynski T; Wonacott AJ; Smith PW; Sollis SL; Howes PD; Cherry PC; Bethell R; Colman P; Varghese J
J Med Chem; 1998 Mar; 41(6):798-807. PubMed ID: 9526556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
